Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hengagliflozin proline
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Hengagliflozin proline (SHR3824) is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor developed by Jiangsu Hengrui Pharmaceuticals. It is formulated as an L-proline cocrystal to enhance its physicochemical properties. The drug was approved by the China National Medical Products Administration (NMPA) in December 2021 for the treatment of type 2 diabetes mellitus, either as monotherapy or in combination with metformin. By inhibiting SGLT2 in the proximal renal tubules, it blocks the reabsorption of filtered glucose, leading to increased urinary glucose excretion and a subsequent reduction in plasma glucose levels. Beyond its primary indication for glycemic control, hengagliflozin proline is being investigated in Phase 4 clinical trials for weight management in obese adults without diabetes, as SGLT2 inhibition is associated with caloric loss and weight reduction.
- Brand names
- Ruiglitin
- Other names
- hengagliflozin proline瑞格列净
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)SLC5A1 (Sodium Glucose Cotransporter 1)
Beyond the preview
Go deeper on hengagliflozin proline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hengagliflozin proline.